Clinical Trial

CD45BE-HSPC + CART-45 Cells

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-11
notable Primary completion pushed: 2043-04 -> 2051-07 2026-05-09
minor Completion pushed: 2043-04 -> 2051-07 2026-05-09
Trial Details
NCT Number NCT07451054
Lead Sponsor University of Pennsylvania
Collaborators: Kite, A Gilead Company
Conditions B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Enrollment 42 participants
Start Date 2026-08-05
Primary Completion 2051-07 (estimated)
Study Completion 2051-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-10